Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 3
2006 4
2007 6
2008 3
2009 2
2010 3
2011 13
2012 18
2013 15
2014 8
2015 9
2016 22
2017 27
2018 13
2019 12
2020 14
2021 8
2022 7
2023 6
2024 5
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the placebo group (95% CI, 5.1 to 6.0; P<0.001). ...Tolvaptan was associated with a slo …
RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval …
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
After an 8-week prerandomization period that included sequential placebo and tolvaptan run-in phases, during which each patient's ability to take tolvaptan without dose-limiting side effects was assessed, 1370 patients with ADPKD who were either 18 to 55 years of ag …
After an 8-week prerandomization period that included sequential placebo and tolvaptan run-in phases, during which each patient's abi …
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F. Mekahli D, et al. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022. Clin J Am Soc Nephrol. 2023. PMID: 36719158 Free PMC article. Clinical Trial.
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). ...In group 1, the 12-month htTKV increase was 2.6% with tolvaptan and 5.8% with placebo (P>0.05). For tolva …
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidne …
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
CONTEXT: Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure. OBJECTIVE: To investigate the effects of tolvaptan initiated in patients hospitalized with heart failure. DES …
CONTEXT: Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for manag …
Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.
Wang L, Zhang Q, Liu M, Chen S, Han S, Li J, Du R. Wang L, et al. J Int Med Res. 2019 Nov;47(11):5414-5425. doi: 10.1177/0300060519882221. Epub 2019 Nov 4. J Int Med Res. 2019. PMID: 31680601 Free PMC article.
OBJECTIVE: In this meta-analysis, we aimed to compare efficacy and clinical outcomes of tolvaptan in treating acute heart failure (AHF). METHODS: Using MEDLINE, we searched relevant clinical studies using tolvaptan that investigated clinical effects in treating AHF. …
OBJECTIVE: In this meta-analysis, we aimed to compare efficacy and clinical outcomes of tolvaptan in treating acute heart failure (AH …
Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis.
Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V. Bellos I, et al. Dig Dis. 2020;38(4):320-328. doi: 10.1159/000503559. Epub 2019 Oct 2. Dig Dis. 2020. PMID: 31578028
The aim of this meta-analysis was to evaluate whether response to treatment with tolvaptan is associated with improved overall survival in cirrhotic patients with refractory ascites. ...Response to tolvaptan was estimated to be linked to significantly improved overa …
The aim of this meta-analysis was to evaluate whether response to treatment with tolvaptan is associated with improved overall surviv …
The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
Li X, Li W, Li Y, Dong C, Zhu P. Li X, et al. Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):731-741. doi: 10.1016/j.nefroe.2023.04.002. Epub 2023 May 5. Nefrologia (Engl Ed). 2023. PMID: 37150675 Free article.
BACKGROUND: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan. Therefore, we aim to systematically estimate and evaluate the efficacy and safety of tolvaptan in the treatmen …
BACKGROUND: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delaye …
Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.
Luo X, Jin Q, Wu Y. Luo X, et al. Pharmacol Res Perspect. 2020 Jun;8(3):e00614. doi: 10.1002/prp2.614. Pharmacol Res Perspect. 2020. PMID: 32500625 Free PMC article.
This study aimed to investigate the short-term efficacy and safety of tolvaptan as an add-on to traditional diuretics in patients with acute heart failure (AHF). ...The protective effects of add-on tolvaptan against WRF, however, were observed at low doses, but not …
This study aimed to investigate the short-term efficacy and safety of tolvaptan as an add-on to traditional diuretics in patients wit …
Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure.
Kansara T, Gandhi H, Majmundar M, Kumar A, Patel JA, Kokkirala A, Moskovits N, Mushiyev S, Basman C. Kansara T, et al. Indian Heart J. 2022 Jan-Feb;74(1):40-44. doi: 10.1016/j.ihj.2021.12.003. Epub 2021 Dec 14. Indian Heart J. 2022. PMID: 34919966 Free PMC article.
We aim to evaluate the additive effect of tolvaptan on efficacy parameters as well as outcomes in hospitalized patients with HF. METHODS: We searched PubMed, EMBASE, Cochrane library, and Web of Science databases for randomized controlled trials that studied the effects of …
We aim to evaluate the additive effect of tolvaptan on efficacy parameters as well as outcomes in hospitalized patients with HF. METH …
Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis.
Bellos I, Kontzoglou K, Perrea DN. Bellos I, et al. J Gastroenterol Hepatol. 2020 Feb;35(2):182-191. doi: 10.1111/jgh.14784. Epub 2019 Aug 16. J Gastroenterol Hepatol. 2020. PMID: 31323125
BACKGROUND AND AIM: Tolvaptan represents an oral V(2) -receptor antagonist, which has been suggested as a promising add-on diuretic treatment for refractory ascites. ...CONCLUSIONS: The present findings suggest bodyweight, BUN, C-reactive protein, and hepatitis C as potent …
BACKGROUND AND AIM: Tolvaptan represents an oral V(2) -receptor antagonist, which has been suggested as a promising add-on diuretic t …
174 results